| Heading: |
Selective Serotonin Reuptake Inhibitors: Sexual Dysfunction |
| Question ID: |
1808301 |
| UIN: |
56571 |
| House: |
Commons |
| Date tabled: |
2025-06-02 |
| Asking Member ID: |
5279 |
| Asking Member display name: |
Jayne Kirkham
|
| Asking Member handle: |
jaynekirkham4
|
| Asking Member Twitter reference: |
@jaynekirkham4
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 13 May 2025 to Question 50758 on Selective Serotonin Reuptake Inhibitors: Sexual Dysfunction, which regulatory options are under consideration; and what his planned timefr |
| Is named day: |
true |
| Date of holding answer: |
|
| Date answered: |
2025-06-05 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
Following the next meeting of the Expert Working group (EWG), the Medicines and Healthcare products Regulatory Agency (MHRA) will seek advice from the Commission on Human Medicines on the recommendations of the EWG, on a wide range of regulatory options f... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |